Read the newsletter by clicking here
A word from the CEO
The intense period in Xintela operations has continued and positively so. Previously, we reported on the good progress of both our regenerative medicine and cancer projects, which continue to develop quickly. We are currently focusing on starting stem cell production according to Good Manufacturing Practice (GMP), as well as obtaining regulatory approval for a clinical equine study.
In this newsletter, Caroline Ehrencrona, one of our key personnel and responsible for liaising with regulatory authorities and planning our clinical development, discusses the coming clinical equine study and how this differs from the preclinical study that we conducted last year at Cornell University.
We also continue to present video interviews in this newsletter. The current video, conducted and published by Biostock, is an interview with Marcus Keep, Doctor and Associate Professor of Neurosurgery working in the USA. He describes glioblastoma and the treatments available today for people affected with this brain tumour and what distinguishes Xintela’s treatment concept for this type of cancer.
Last, but not least, we are very pleased with the results of the recent warrant program and discuss this in more detail in this newsletter.
CEO Evy Lundgren-Åkerlund
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO